PB

Paul Burton

Managing Partner 2Flo Ventures

Evanston, Illinois

Invests in

Stages:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Work Experience

  • Member Board of Directors

    2023

    Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), is an AI-driven precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease.

  • Managing Partner

    2021

    2Flo Ventures is an early-stage healthcare investor and start-up studio. We aim to facilitate the flow of innovation, talent and other resources to-and-fro underserved communities and reduce disparities in healthcare outcomes. We are focused on advancing innovations that impact the disenfranchised while also addressing the lack of African American participation within healthcare innovation. We believe that our nation's glaring health disparities are a by-product of inadequate representation of AAs within the C-Suite level of VC backed healthcare startups. 2Flo holds the promise to be part of the solution to our health disparities and provide an attractive return to investors.

2015

  • Member

    2015

    MATTER is a health tech hub that "​ illuminates the path to success through mentorship, networking and shared resources. We provide a sense of community among members and extend out to the greater healthcare network, both locally and globally".

  • Managing Principal

    2010

    Financial and strategic advisory services to businesses and families. Including assistance in capital raising, M&A, investor relations, investment management, succession planing and generally business planning. The firm also provides life, disability and long-term care insurance brokerage and retirement planning services.

  • Chief Executive Officer

    2018

    Akan Bio is a biotechnology and cellular therapy company developing next generation injectable products for the treatment of degenerative diseases and injury. Akan Bio is developing cellular therapies and proprietary manufacturing methods to produce stem cell based therapeutics with state-of-the art tissue engineering. The Company has started clinical trials for osteoarthritis of knee and expects to complete phase I in first quarter of 2022.

2019 - 2022

  • Chief Financial Officer

    2019 - 2022

  • Entrepreneur In Residence

    2019 - 2021

    The Garage at Northwestern is a cross-disciplinary space designed for all Northwestern students to explore innovation and entrepreneurship.

2015 - 2018

  • Chief Executive Officer

    2015 - 2018

    ResQ Pharma is a research & development company. Its lead program, LipidRescue Therapy (LRT) is an already widely recommended off-label treatment for drug poisoning and toxicity that has a clear and concise path to FDA approval and market entry in a specially designed formulation.

2012 - 2015

  • Chief Financial Officer

    2012 - 2015

    Vivacelle Bio, Inc. (VBI) is a clinical stage biotechnology company focused on creating new approaches to injury and disease utilizing nano-micelle or liposomal technology. The company's first product is a novel advanced colloidal volume expander for sustaining life during severe episodes of hypovolemia and hypotension due to fluid or blood loss.

  • Principal

    2004 - 2010

    Pursued and managed equity and mezzanine investments in commercial real estate and privately held businesses. Provided financial and strategic consulting services to small businesses.